Other languages CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 26/04/2024 pm IST			5-day change	1st Jan Change
0.9 ^HKD	0.00%		+5.88%	-60.35%

24/04	Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	MT
23/04	CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	24/04
CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	24/04
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor	09/04
CStone Announces the Availability of RET Inhibitor GAVRETO® Manufacturing Localization Application by Center for Drug Evalence of China NMPA	09/04
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved	15/03
CStone Pharmaceuticals Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer	15/03
CStone Pharmaceuticals Booted From Hong Kong Stock Connect; Shares Plunge 25%	04/03
CStone Pharmaceuticals Arm to Sell Ivosidenib Business for $50 Million	21/12
China Includes CStone's Gastrointestinal Stromal Tumor Treatment in National Reimbursement List; Shares Jump 6%	13/12
China Approves CStone Pharma's Treatment for Esophageal Squamous Cell Carcinoma; Shares Soar 21%	08/12
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab as First-Line Treatment for Esophageal Squamous Cell Carcinoma	08/12
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	02/11
CStone Pharmaceuticals Announces Strategic Partnership and Exclusive Licensing Agreement with Shenyang Sunshine Pharmaceuticals Co., Ltd for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China	01/11
CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3Sbio for Nofazinlimab (ANTI-PD-1 Antibody) in Mainland China	01/11
CStone Pharmaceuticals Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma	31/23/31
China Approves CStone's Lymphoma Medication	31/23/31
CStone Pharmaceutical Awaits Chinese Approval for Anti-Cancer Drug	24/23/24
CStone Pharmaceuticals Announces Results from A Pivotal Phase III Clinical Trial (GEMSTONE-303), Evaluating Sugemalimab in First-Line GASTRIC or Gastesophageal Junction Adenocarcinoma	24/23/24
CStone CEO to Boost Share Count; Shares Fall 9%	03/23/03
CStone Pharmaceuticals Announces Registrational Trial of Sugemalimab in First-Line Gastric or Gastroesophageal Junction Adenocarcinoma Met Primary Endpoint of Overall Survival	29/23/29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Other languages

Filters